Literature DB >> 29088340

Corrigendum: Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management.

Marcus Harbord1, Rami Eliakim2, Dominik Bettenworth3, Konstantinos Karmiris4, Konstantinos Katsanos5, Uri Kopylov6, Torsten Kucharzik7, Tamás Molnár8, Tim Raine9, Shaji Sebastian10, Helena Tavares de Sousa11, Axel Dignass12, Franck Carbonnel13.   

Abstract

Entities:  

Year:  2017        PMID： 29088340     DOI： 10.1093/ecco-jcc/jjx105

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN： 1873-9946            Impact factor:   9.071


× No keyword cloud information.
  12 in total

Review 1.  Management of Inflammatory Bowel Disease-Associated Dysplasia in the Modern Era.

Authors:  Shailja C Shah; Steven H Itzkowitz
Journal:  Gastrointest Endosc Clin N Am       Date:  2019-04-06

Review 2.  Diagnosis and management of inflammatory bowel disease-associated neoplasia: considerations in the modern era.

Authors:  Jordan E Axelrad; Shailja C Shah
Journal:  Therap Adv Gastroenterol       Date:  2020-05-06       Impact factor: 4.409

Review 3.  Targeting NF-κB pathway for treating ulcerative colitis: comprehensive regulatory characteristics of Chinese medicines.

Authors:  Peng-De Lu; Yong-Hua Zhao
Journal:  Chin Med       Date:  2020-02-10       Impact factor: 5.455

4.  Induced organoids derived from patients with ulcerative colitis recapitulate colitic reactivity.

Authors:  Samaneh K Sarvestani; Steven Signs; Bo Hu; Yunku Yeu; Hao Feng; Ying Ni; David R Hill; Robert C Fisher; Sylvain Ferrandon; Reece K DeHaan; Jennifer Stiene; Michael Cruise; Tae Hyun Hwang; Xiling Shen; Jason R Spence; Emina H Huang
Journal:  Nat Commun       Date:  2021-01-11       Impact factor: 14.919

5.  Infliximab is effective in the treatment of ulcerative colitis with dermatomyositis: A case report.

Authors:  Bin-Bin Huang; Li-Chun Han; Geng-Feng Liu; Xiao-Dan Lv; Guang-Li Gu; Shi-Quan Li; Lan Chen; Hui-Qin Wang; Ling-Ling Zhan; Xiao-Ping Lv
Journal:  World J Gastroenterol       Date:  2020-12-14       Impact factor: 5.742

6.  LncRNA LUCAT1 as a Plasma Biomarker for Assessing Disease Activity in Adult Patients with Crohn's Disease.

Authors:  Xiao-Yi Kuai; Shun-Ying Yu; Xiu-Fang Cui; Xiao-Jing Zhao; Xia-Qiong Mao; Yang Yu; Tong Hu; Hong-Jie Zhang; Chun-Li Zhou
Journal:  Gastroenterol Res Pract       Date:  2021-09-28       Impact factor: 2.260

7.  Drug Lag for Inflammatory Bowel Disease Treatments in the East and West.

Authors:  Shinji Okabayashi; Taku Kobayashi; Toshifumi Hibi
Journal:  Inflamm Intest Dis       Date:  2018-10-05

8.  Clostridium difficile infection in hospitalized patients with inflammatory bowel disease: Prevalence, risk factors, and prognosis.

Authors:  Nitsan Maharshak; Idan Barzilay; Hasya Zinger; Keren Hod; Iris Dotan
Journal:  Medicine (Baltimore)       Date:  2018-02       Impact factor: 1.889

9.  IgA, albumin, and eosinopenia as early indicators of cytomegalovirus infection in patients with acute ulcerative colitis.

Authors:  Hong Yang; Kaichun Wu; Hongjie Zhang; Qin Owyang; Yinglei Miao; Fang Gu; Naizhong Hu; Kaifang Zou; Jianqiu Sheng; Jin Li; Ping Zheng; Yulan Liu; Junxia Li; Xiaodi Wang; Yongdong Wu; Yaozong Yuan; Chunxiao Chen; Yanhua Pang; Meihua Cui; Jiaming Qian
Journal:  BMC Gastroenterol       Date:  2020-09-05       Impact factor: 3.067

10.  Lymphocyte Activation Gene (LAG)-3 Is Associated With Mucosal Inflammation and Disease Activity in Ulcerative Colitis.

Authors:  Stephanie M Slevin; Lucy C Garner; Conor Lahiff; Malcolm Tan; Lai Mun Wang; Helen Ferry; Borgel Greenaway; Kate Lynch; Alessandra Geremia; Stephen Hughes; Karen Leavens; David Krull; Daniel J B Marks; Katherine Nevin; Kevin Page; Naren Srinivasan; Ruth Tarzi; Paul Klenerman; Simon Travis; Carolina V Arancibia-Cárcamo; Satish Keshav
Journal:  J Crohns Colitis       Date:  2020-10-05       Impact factor: 9.071
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.